Neurocrine Biosciences
NBIX
#1457
Rank
S$15.96 B
Marketcap
$157.67
Share price
-4.42%
Change (1 day)
7.61%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Revenue for Neurocrine Biosciences (NBIX)

Revenue in 2024 (TTM): S$2.97 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current revenue (TTM ) is S$3.01 Billion. In 2023 the company made a revenue of S$2.49 Billion an increase over the revenue in the year 2022 that were of S$1.99 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Neurocrine Biosciences from 1996 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) S$2.97 B19.29%
2023 S$2.49 B24.88%
2022 S$1.99 B30.24%
2021 S$1.53 B10.75%
2020 S$1.38 B30.24%
2019 S$1.06 B72.34%
2018 S$0.61 B185.17%
2017 S$0.21 B895.76%
2016 S$21.7 M-22.37%
2015 S$27.96 M
2014 N/A-100%
2013 S$3.69 M-94.31%
2012 S$64.98 M-35.18%
2011 S$0.10 B132.32%
2010 S$43.15 M940.91%
2009 S$4.14 M-27.07%
2008 S$5.68 M222.75%
2007 S$1.76 M-97.07%
2006 S$60.16 M-70.83%
2005 S$0.20 B48.45%
2004 S$0.13 B-41.19%
2003 S$0.23 B654.67%
2002 S$31.31 M-58.99%
2001 S$76.34 M201.97%
2000 S$25.28 M-9.67%
1999 S$27.98 M5.95%
1998 S$26.41 M-39.97%
1997 S$44 M63.77%
1996 S$26.87 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
S$0.80 B-73.14%๐Ÿ‡บ๐Ÿ‡ธ USA
S$3.00 B-0.23%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$6.02 M-99.80%๐Ÿ‡บ๐Ÿ‡ธ USA
S$54.86 B 1,721.98%๐Ÿ‡บ๐Ÿ‡ธ USA
S$73.84 B 2,352.29%๐Ÿ‡บ๐Ÿ‡ธ USA
S$74.70 B 2,380.92%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.72 B-75.97%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.1 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA